MINNEAPOLIS (June 15, 2017) – OneOme today launched a product update that makes improvements to its RightMed® pharmacogenomic test workflow, report and interactive application. OneOme’s updates incorporate customer feedback to optimize its product, with the goal of bringing the power of pharmacogenomics into everyday clinical care.
“OneOme is continually improving our products to fulfill our core mission of making affordable pharmacogenomic testing widely available and clinically relevant,” Paul Owen, CEO of OneOme, said. “This launch reinforces our commitment to listening to our customers and offering the highest-quality testing that is easy to use and interpret for medical professionals and patients. We believe our latest RightMed product has an even greater potential to improve health and help patients avoid potentially dangerous adverse drug reactions.”
Pharmacogenomics (PGx) is an emerging field that combines the study of how drugs affect our bodies (pharmacology) with the study of our genes and their functions (genomics). OneOme’s RightMed pharmacogenomic test uses the power of DNA to predict which medications may work best for an individual patient – helping patients to avoid adverse drug reactions and providers to better treat conditions including mental health, heart disease and cancer.
This RightMed product release includes these important updates:
- Optimized ordering workflow streamlines the ordering process with new features that allow medical professionals to add a patient’s current, past or future prescriptions up front;
- Optimized workflow to retrieve results so that providers have easier access to clinical test results and custom RightMed Advisor reports;
- Improved RightMed Advisor that makes it easier and more efficient for providers to navigate the interactive tool and put the most relevant information at the fingertips of healthcare providers; and
- Simplified PGx reports that include new annotations and definitions for drug binning and other improvements to make the report more intuitive and actionable.
OneOme’s latest product offering builds on its reputation and commitment to being easy-to-use, intuitive and integrated into everyday clinical practice. To guide providers through the new reports and portal, OneOme will host a webinar to review the product updates on June 20, 2017 at 2:00 p.m. CT.
The RightMed pharmacogenomic test covers 22 genes, allows clinicians to make decisions across more than 340 medications for more than 20 medical indications, and can be integrated into electronic medical records (EMRs). For providers and pharmacists, the RightMed test also includes the RightMed Advisor, an online, interactive tool for accessing OneOme’s expertly curated pharmacogenomic database. The tool provides insight into the pharmacologic impact of genomic variants and drug-to-drug interactions, a summary of pharmacogenomic clinical guidelines and curated lists of alternative medications.
In addition to improving its products, OneOme is actively working to further the medical research of pharmacogenomic testing. OneOme announced this month it is collaborating with Mayo Clinic and Baylor on the nation’s largest population-based pharmacogenomics study.
Adverse drug reactions are now the fourth leading cause of death in the U.S., and many of the four billion prescriptions issued each year do not work as intended. The RightMed pharmacogenomic test minimizes those risks by using an individual’s DNA to predict how medications will work for that patient. Integrating these results into a patient’s EMR gives doctors the ability to use the results to prescribe medications more effectively for years to come.
Anyone can take the RightMed test, although patients who may benefit most include: those who are taking certain classes of medication, such as cardiovascular or psychiatric prescriptions; those who are struggling with adverse drug reactions or medications that are not working; or those who are on multiple medications.
The OneOme platform was co-developed and exclusively licensed from Mayo Clinic to bring pharmacogenomics into routine clinical care. OneOme is a privately held company backed by early-stage venture firm Invenshure, LLC, and Mayo Clinic. To learn more about OneOme, visit oneome.com.